Literature DB >> 2242037

[3H]mecamylamine binding to rat brain membranes. Studies with mecamylamine and nicotine analogues.

S Banerjee1, J S Punzi, K Kreilick, L G Abood.   

Abstract

Mecamylamine, an antagonist to nicotine, does not compete at the nicotinic recognition site, but is believed to block the ion channel of the nicotinic receptor. The present study demonstrates specific, saturable [3H]mecamylamine binding in rat brain membranes. [3H]Mecamylamine binding was destroyed by heating at 100 degrees and trypsin. Scatchard analysis revealed the presence of two sites with Kd values of 9.6 x 10(-8) and 1.1 x 10(-6) M and Bmax values of 7 x 10(-12) and 3 x 10(-11) mol/mg protein respectively. A good correlation was observed between the Ki values for [3H]mecamylamine binding of a number of mecamylamine and related analogues and their ability to block nicotine-induced prostration in rats and seizures in mice. Inorganic cations, particularly divalent, and various ion channel blockers, such as phencyclidine and verapamil, exhibited a high affinity for the [3H]mecamylamine site. Although mecamylamine did not block nicotine binding, nicotine and its analogues exhibited a high affinity for the [3H]mecamylamine site, a finding which suggests that nicotine acts directly on ion channels as well as the nicotinic cholinergic recognition sites. The data are consistent with the notion that mecamylamine interacts with the open ion channel of the nicotinic receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242037     DOI: 10.1016/0006-2952(90)90241-c

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Pharmacol Biochem Behav       Date:  2019-02-06       Impact factor: 3.533

Review 2.  Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.

Authors:  Lance R McMahon
Journal:  Expert Rev Clin Pharmacol       Date:  2019-01-24       Impact factor: 5.045

3.  4-Bromoacetamidoprocaine: an affinity ligand for brain muscarinic and nicotinic cholinergic receptors.

Authors:  M Saraswati; M Hashmi; L G Abood
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

4.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 5.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

Review 6.  Cholinergic modulation of the cortical neuronal network.

Authors:  E Lucas-Meunier; P Fossier; G Baux; M Amar
Journal:  Pflugers Arch       Date:  2003-03-05       Impact factor: 3.657

7.  The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

8.  The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat.

Authors:  D H Malin; J R Lake; V A Carter; J S Cunningham; K M Hebert; D L Conrad; O B Wilson
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-β-erythroidine in nicotine-tolerant mice.

Authors:  Fernando B de Moura; Jenny L Wilkerson; Lance R McMahon
Journal:  Brain Behav       Date:  2020-02-24       Impact factor: 2.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.